Abstract:Abstract Background: The ypTNM stage and tumor regression grading (TRG) is widely used to predict the efficacy of neoadjuvant chemotherapy (NAC). However, the potential prognostic role of molecular markers is unknown. There is growing evidence assessing the predictive impact of tumor mutational burden (TMB) on the clinical efficiency of immunotherapy, but few investigation has pursued the predictive value of TMB on the efficiency of neoadjuvant chemotherapy. In this study, the prognostic role of TMB and tumor markers for NAC in patients with GC were explored. Methods: Patients with Stage II/III gastric adenocarcinoma (n = 30) were enrolled in this study between Jan 2016 and Jun 2017 in Peking University Cancer Hospital. All patients were subjected to NAC before resection. Whole exome sequencing (WES) were implemented on the biopsy samples collected from the 30 patients before NAC .Tumor mutation burden (TMB) of total somatic substitutions and indels per megabase after fıltering known driver mutations were calculated. The five postoperative serum tumor markers: AFP,CEA,CA199,CA724 and CA242 were quantitatively measured before and after operation. Results: Of all the 30 patients with GC receiving neoadjuvant chemotherapy before resection, 12 patients (40.0%) with higher TMB (≥5 mutations per Mb) showed significantly better prognosis compared to the other 18 patients (P=0.019, HR=6.042). And all these 12 patients survived at follow-up. In patients with TMB<5, those who with tumor marker positive (TM+) postoperatively were at more risk of recurrence than patients with negative TM (TM-) in postoperative plasma. Compared to the patients with TMB≥5, the subgroup of both TMB<5 & TM- (P = 0.0631, HR= 6.449) and TMB<5 & TM+ (P <0.0001, HR=1303) had poorer survival. The results showed that TMB combined with TM (Log-rank test, P<0.0001) provide better predictive validity on prognostic value compared with ypTNM alone (Log-rank test, P=0.1534). In addition, whole exome sequencing data from 478 STAD patients (Stomach Adenocarcinoma (TCGA, Provisional)) obtained from TCGA were used to detect somatic mutations. The results also indicated that mutation count was the most relevant clinical attribute of overall survival (Kruskal Wallis Test, q-value<10−10). It is further suggested that TMB is related to prognosis. Conclusions: In patients with GC, higher TMB levels (TMB≥5) of biopsy tissue before NAC showed greater response rates for neoadjuvant chemotherapy and longer survival. TMB<5 together with TM+ was a strong and accessible biomarker of poor OS. This is the first report of TMB can be used as a predictive biomarker before NAC, and TMB combined with tumor markers (TM) were significantly associated with prognosis in patients with Gastric Cancer. Additional larger cohort study aimed at understanding relationship between response to therapy and TMB are further required. Citation Format: Yongning Jia, Honglin Zhu, Fei Pang, Fei Shan, Shuangxi Li, Lei Dong, Tonghui Ma, Ziyu Li. Tumor mutation burden combined with tumor markers as predictive prognostic biomarkers for neoadjuvant chemotherapy in patients with gastric cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 6467.

Tumor regression grade combined with post‐therapy lymph node status: A novel independent prognostic factor for patients treated with neoadjuvant therapy followed by surgery in locally advanced gastroesophageal junction and gastric carcinoma

Clinical Significance of Tumor Deposits in Gastric Cancer: a Retrospective and Propensity Score-Matched Study at Two Institutions

Prognostic Factors in Stage I Gastric Cancer: A Retrospective Analysis

Clinicopathologic variables predicting tumor response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer.

Prognostic Value of Tumor Regression Grading in Patients Treated With Neoadjuvant Chemotherapy Plus Surgery for Gastric Cancer

Role of pathological tumor regression grade of lymph node metastasis following neoadjuvant chemotherapy in locally advanced gastric cancer

Prognostic Value of Tumor Deposits in Lymph Node-Negative Gastric Cancer: A Propensity Score Matching Study.

Tumor Regression Grade As a Prognostic Factor in Metastatic Colon Cancer Following Preoperative Chemotherapy

College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer.

The Ypt May Better Predict the Efficacy of Neoadjuvant Chemoradiotherapy Than Tumor Regression Grade in Locally Advanced Rectal Cancer Patients Diagnosed Ypt1-4N0.

The Correlation Between Tumor Regression Grade and Retrieved Lymph Nodes Status in Locally Advanced Rectal Cancer after Neoadjuvant Treatment: Results from a Prospective Study

New Tumour Regression Grade for Rectal Cancer after Neoadjuvant Therapy and Radical Surgery

Prognostic Value of Neutrophil–Lymphocyte Ratio, Platelet–Lymphocyte Ratio, and Combined Neutrophil–Lymphocyte Ratio and Platelet–Lymphocyte Ratio in Stage IV Advanced Gastric Cancer

Nomograms to predict tumor regression grade (TRG) and ypTNM staging in patients with locally advanced esophageal cancer receiving neoadjuvant therapy

Comparison of tumor regression grading systems for locally advanced gastric adenocarcinoma after neoadjuvant chemotherapy

Predictive value of NLR and PLR in response to preoperative chemotherapy and prognosis in locally advanced gastric cancer

The prognostic significance of the treatment response of regional lymph nodes and the refinement of the current TNM staging system in locally advanced rectal cancer after neoadjuvant chemoradiotherapy

Abstract 6467: Tumor Mutation Burden Combined with Tumor Markers As Predictive Prognostic Biomarkers for Neoadjuvant Chemotherapy in Patients with Gastric Cancer

Can Tumor Regression Grade Influence Survival Outcome in Ypt3 Rectal Cancer?

More than 16 lymphatic metastasis ( pN 3 b ) of resectable gastric cancer ( GC ) associated with inferior prognosis of patients : a large sample single-center retrospective study

Prognostic value of pathological tumor regression grade in locally advanced gastric cancer: New perspectives from a single‐center experience